Langlois A J, Desrosiers R C, Lewis M G, KewalRamani V N, Littman D R, Zhou J Y, Manson K, Wyand M S, Bolognesi D P, Montefiori D C
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
J Virol. 1998 Aug;72(8):6950-5. doi: 10.1128/JVI.72.8.6950-6955.1998.
Infection with attenuated simian immunodeficiency virus (SIV) in rhesus macaques has been shown to raise antibodies capable of neutralizing an animal challenge stock of primary SIVmac251 in CEMx174 cells that correlate with resistance to infection after experimental challenge with this virulent virus (M. S. Wyand, K. H. Manson, M. Garcia-Moll, D. C. Montefiori, and R. C. Desrosiers, J. Virol. 70:3724-3733, 1996). Here we show that these neutralizing antibodies are not detected in human and rhesus peripheral blood mononuclear cells (PBMC). In addition, neutralization of primary SIVmac251 in human and rhesus PBMC was rarely detected with plasma samples from a similar group of animals that had been infected either with SIVmac239Deltanef for 1.5 years or with SIVmac239Delta3 for 3.2 years, although low-level neutralization was detected in CEMx174 cells. Potent neutralization was detected in CEMx174 cells when the latter plasma samples were assessed with laboratory-adapted SIVmac251. In contrast to primary SIVmac251, laboratory-adapted SIVmac251 did not replicate in human and rhesus PBMC despite its ability to utilize CCR5, Bonzo/STRL33, and BOB/gpr15 as coreceptors for virus entry. These results illustrate the importance of virus passage history and the choice of indicator cells for making assessments of neutralizing antibodies to lentiviruses such as SIV. They also demonstrate that primary SIVmac251 is less sensitive to neutralization in human and rhesus PBMC than it is in established cell lines. Results obtained in PBMC did not support a role for neutralizing antibodies as a mechanism of protection in animals immunized with attenuated SIV and challenged with primary SIVmac251.
恒河猴感染减毒猿猴免疫缺陷病毒(SIV)后,已证明会产生能够中和CEMx174细胞中初代SIVmac251动物攻击毒株的抗体,这些抗体与实验性感染这种强毒病毒后的抗感染能力相关(M. S. 怀安德、K. H. 曼森、M. 加西亚 - 莫尔、D. C. 蒙特菲奥里和R. C. 德罗西耶,《病毒学杂志》70:3724 - 3733, 1996)。在此我们表明,在人和恒河猴外周血单个核细胞(PBMC)中未检测到这些中和抗体。此外,用来自一组相似动物的血浆样本对人和恒河猴PBMC中的初代SIVmac251进行中和时,这些动物分别感染SIVmac239Deltanef达1.5年或感染SIVmac239Delta3达3.2年,虽然在CEMx174细胞中检测到了低水平中和,但在人和恒河猴PBMC中很少检测到中和现象。当用实验室适应的SIVmac251评估后者的血浆样本时,在CEMx174细胞中检测到了强效中和。与初代SIVmac251不同,实验室适应的SIVmac251尽管能够利用CCR5、Bonzo/STRL33和BOB/gpr15作为病毒进入的共受体,但在人和恒河猴PBMC中不复制。这些结果说明了病毒传代历史以及用于评估针对诸如SIV等慢病毒的中和抗体的指示细胞选择的重要性。它们还表明,初代SIVmac251在人和恒河猴PBMC中比在已建立的细胞系中对中和更不敏感。在PBMC中获得的结果不支持中和抗体作为在用减毒SIV免疫并接受初代SIVmac251攻击的动物中的一种保护机制所起的作用。